Skip to content
Nonprofiteer
← QUANTUM LEAP HEALTH CARECOLLABORATIVE

Form 990 for tax year 2022

Filed by QUANTUM LEAP HEALTH CARECOLLABORATIVE.

Totals

Total revenue
$47,253,845
Total expenses
$47,240,395
Contributions and grants received
$18,937,275
Grants paid
$0
Program service revenue
$27,865,728
Investment income
$450,842
Other revenue
$0
Total assets, end of year
$60,913,948
Total liabilities, end of year
$30,870,765
Net assets or fund balances, end of year
$30,043,183
Program services expenses (Part IX)
$44,382,279
Management and general expenses
$2,605,067
Fundraising expenses
$253,049
Program service expenses (Part III)
$44,382,279

Program services were 93.9% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1e · Government grants (contributions)

    $17,468,384

  • 1f · All other contributions, gifts and grants

    $1,468,891

  • 1g · Noncash contributions included above

    $741,884

  • 2a · Program service revenue: CLINICAL TRIAL CONTRAC

    total $26,914,608 · related or exempt $26,914,608

  • 2b · Program service revenue: CONSULTING AND RESEARC

    total $951,120 · related or exempt $951,120

  • 3 · Investment income

    total $517,557 · excluded $517,557

  • 7a · Gross sales of assets other than inventory

    securities $83,595,130

  • 7b · Less cost or other basis and sales expenses

    securities $83,661,845

  • 7c · Gain or loss

    securities -$66,715

  • 7d · Net gain or loss

    total -$66,715 · excluded -$66,715

Functional expenses

Part IX, the statement of functional expenses.

  • 5 · Compensation of officers, directors and key employees

    total $1,090,719 · program services $1,036,184 · management and general $54,535

  • 7 · Other salaries and wages

    total $12,102,560 · program services $10,702,036 · management and general $1,217,124 · fundraising $183,400

  • 8 · Pension plan contributions

    total $314,326 · program services $278,211 · management and general $31,412 · fundraising $4,703

  • 9 · Other employee benefits

    total $1,750,484 · program services $1,554,396 · management and general $171,056 · fundraising $25,032

  • 10 · Payroll taxes

    total $897,490 · program services $798,244 · management and general $86,709 · fundraising $12,537

  • 11b · Fees: legal

    total $143,333 · management and general $143,333

  • 11c · Fees: accounting

    total $465,350 · management and general $465,350

  • 11f · Fees: investment management

    total $5,974 · management and general $5,974

  • 11g · Fees: other

    total $1,043,036 · program services $967,318 · management and general $72,380 · fundraising $3,338

  • 12 · Advertising and promotion

    total $116,000 · program services $102,723 · management and general $12,995 · fundraising $282

  • 13 · Office expenses

    total $1,277,193 · program services $1,190,520 · management and general $79,765 · fundraising $6,908

  • 14 · Information technology

    total $8,167,801 · program services $8,052,394 · management and general $103,322 · fundraising $12,085

  • 15 · Royalties

    total $448,362 · program services $448,362

  • 16 · Occupancy

    total $292,248 · program services $174,853 · management and general $115,714 · fundraising $1,681

  • 17 · Travel

    total $289,206 · program services $271,836 · management and general $16,378 · fundraising $992

  • 19 · Conferences, conventions and meetings

    total $230,567 · program services $216,719 · management and general $13,057 · fundraising $791

  • 20 · Interest

    total $1,123 · program services $930 · management and general $157 · fundraising $36

  • 22 · Depreciation, depletion and amortization

    total $95,350 · program services $82,435 · management and general $12,227 · fundraising $688

  • 23 · Insurance

    total $56,511 · program services $54,143 · management and general $2,122 · fundraising $246

  • 24a · Other expenses: PROGRAM MANAGEMENT

    total $10,420,794 · program services $10,420,794

  • 24b · Other expenses: RESEARCH SITES

    total $6,117,052 · program services $6,117,052

  • 24c · Other expenses: RESEARCH

    total $1,904,475 · program services $1,904,475

  • 24d · Other expenses: OTHER

    total $10,441 · program services $8,654 · management and general $1,457 · fundraising $330

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $3,320,860 · end of year $4,269,894

  • 2 · Savings and temporary cash investments

    beginning of year $44,752,067 · end of year $4,943,974

  • 3 · Pledges and grants receivable

    beginning of year $1,775,471 · end of year $1,438,761

  • 4 · Accounts receivable

    beginning of year $4,913,529 · end of year $11,320,172

  • 8 · Inventories for sale or use

    beginning of year $2,884

  • 9 · Prepaid expenses and deferred charges

    beginning of year $1,802,060 · end of year $636,230

  • 10a · Land, buildings and equipment: cost or other basis

    $324,892

  • 10b · Land, buildings and equipment: accumulated depreciation

    $172,229

  • 10c · Land, buildings and equipment, net

    beginning of year $210,502 · end of year $152,663

  • 11 · Investments: publicly traded securities

    beginning of year $7,666,055 · end of year $37,862,213

  • 15 · Other assets

    beginning of year $0 · end of year $290,041

  • 17 · Accounts payable and accrued expenses

    beginning of year $25,408,456 · end of year $18,472,283

  • 19 · Deferred revenue

    beginning of year $8,432,250 · end of year $10,935,289

  • 25 · Other liabilities

    beginning of year $0 · end of year $1,463,193

  • 27 · Net assets without donor restrictions

    beginning of year $28,731,090 · end of year $29,720,498

  • 28 · Net assets with donor restrictions

    beginning of year $1,871,632 · end of year $322,685

Mission and programs · 2022

Mission

THE MISSION OF QUANTUM LEAP HEALTHCARE COLLARBORATIVE IS TO PROVIDE MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT.

Activities or mission (Part I)

THE MISSION OF QUANTUM LEAP HEALTHCARE COLLARBORATIVE IS TO PROVIDE (CONTINUED ON SCH. O)MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT.

  • I-SPY TRIALS: QUANTUM LEAP SPONSORS THE I-SPY TRIALS (INVESTIGATION OF SERIAL STUDIES TO PREDICT YOUR THERAPEUTIC RESPONSE WITH IMAGING AND MOLECULAR ANALYSIS). I-SPY HAS BEEN RE-ENGINEERING THE APPROACH TO CLINICAL TRIALS, WITH A GOAL OF GETTING THE RIGHT DRUG TO THE RIGHT PATIENT AT THE TIME WHEN THEY WILL BENEFIT MOST, AND TO ACHIEVE THIS FASTER THAN POSSIBLE IN PREVIOUS TRIAL MODELS. ADDITIONALLY, I-SPY AIMS TO SIGNIFICANTLY REDUCE THE OVERALL COST, TIME, AND NUMBER OF PATIENTS REQUIRED TO BRING NEW DRUGS TO MARKET. THE I-SPY TRIAL PROGRAM INTEGRATES AND LINKS PHASE I (I-SPY PHASE 1), PHASE II (I-SPY 2), AND FUTURE PHASES TO BUILD A PIPELINE OF NOVEL AGENTS AND ACCELERATE THE PROCESS OF IDENTIFYING THE SUBSET OF HIGH-RISK BREAST CANCER PATIENTS THAT WILL BENEFIT FROM THESE NEW AGENTS, AND GET THESE DRUG INTO THE CLINIC IN A TIMELY MANNER.

    Expenses $22,845,603 · Revenue $26,360,608

  • DURING FISCAL YEAR 2020, THE I-SPY COVID TRIAL AN ADAPTIVE PLATFORM TRIAL, WAS DESIGNED TO RAPIDLY SCREEN AND CONFIRM HIGH IMPACT TREATMENTS TO REDUCE MORTALITY AND TIME ON VENTILATORS. THIS WORK IS INDEPENDENT AND EQUALLY AS IMPORTANT AS VACCINE EFFORTS. I-SPY COVID TRIAL FOCUSES ON THOSE PATIENTS WHOSE REACTIONS TO THE VIRUS MAKE THEM CRITICALLY ILL AND, IN MANY CASES, RESULTS IN DEATH. THE PRIMARY FOCUS OF THE TRIAL WAS TO IDENTIFY PROMISING DRUGS THAT EITHER NEUTRALIZE THE VIRUS, HELP HEAL THE LUNG DAMAGE FROM THE VIRUS (CAUSED BY ADULT RESPIRATORY DISTRESS SYNDROME OR (ARDS) OR TO CHANGE THE IMMUNE SYSTEM REACTION WHICH RESULTS IN ILLNESS (FOR YOUNGER PEOPLE, THIS IS ESPECIALLY IMPORTANT). THE TRIAL OPENED JUNE 2020 AND WILL CONTINUE TO RUN UNTIL A DRUG OR COMBINATIONS OF DRUGS, IS FOUND THAT PREVENTS THE NECESSITY FOR VENTILATION TREATMENT AND ELIMINATES DEATH FROM THE DISEASE.

    Expenses $20,050,960 · Revenue $554,000

  • BREAST CANCER TRIALS (BCT) - LAUNCHED IN 2008, FOLLOWING A SUCCESSFUL UCSF-NCI SPONSORED RESEARCH PILOT, ITS MISSION IS TO MAKE PATIENT CONSIDERATION OF TRIALS THE NORM VS. THE EXCEPTION. WE BELIEVE THAT ALL PATIENTS SHOULD HAVE ACCESS TO THE LATEST MEDICAL KNOWLEDGE ABOUT BREAST CANCER TREATMENT AS WELL AS THE OPPORTUNITY TO ADVANCE BREAST CANCER RESEARCH. BCT LISTS OVER 600 STUDIES FOR PEOPLE WITH NEWLY DIAGNOSED BREAST CANCER, METASTATIC DISEASE, OR POST-TREATMENT SURVIVORS. IT INCLUDES INNOVATIVE TRIALS OF TARGETED AND IMMUNOTHERAPIES AS WELL AS OBSERVATIONAL STUDIES LOOKING AT QUALITY OF LIFE, GENETIC MUTATIONS, AND BREAST CANCER SURVIVORSHIP, ACCOMPANIED BY EASY-TO-READ TRIAL SUMMARIES.

    Expenses $1,207,919 · Revenue $62,500

  • Expenses $277,797 · Revenue $888,620

As filed on the 2022 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • Dave Mandelkern

    CHAIRMAN

    Total calculated
    $120,000
    From this org
    $120,000
    From related orgs
    $0
    Other
    $0
    Hours/week
    12

  • Laura Esserman

    DIRECTOR, COFOUNDER

    Total calculated
    $0
    Hours/week
    20

  • Jeffrey Pfeffer

    DIRECTOR, COFOUNDER

    Total calculated
    $0
    Hours/week
    0.5

  • Susan Foley

    TREASURER

    Total calculated
    $0
    Hours/week
    0.5

  • Anna Barker

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5

  • Lucas De Breed

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5

  • Michele Markus

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5

  • Robert Patterson

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5

  • Robyn Lawrie Rutledge

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5

  • Gregory C Simon

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5

  • Mark Simon

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5

  • N Marcus Thygeson

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5

  • Lambert Van Der Walde

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5

  • Kathryn Watson-Feiner

    VICE PRESIDENT OF FINANCE AND ADMINISTRATION

    Total calculated
    $318,418
    From this org
    $305,989
    From related orgs
    $0
    Other
    $12,429
    Hours/week
    60

    Schedule J breakdown matched by us

    Base
    $296,388
    Bonus
    $9,601
    Other
    $0
    Deferred
    $9,724
    Nontaxable benefits
    $2,705
    Filer's total
    $318,418

  • James Palazzolo

    CEO

    Total calculated
    $548,746
    From this org
    $508,333
    From related orgs
    $0
    Other
    $40,413
    Hours/week
    60

    Schedule J breakdown matched by us

    Base
    $433,333
    Bonus
    $75,000
    Other
    $0
    Deferred
    $4,167
    Nontaxable benefits
    $36,246
    Filer's total
    $548,746

  • Adam Asare

    CHIEF DATA OFFICER

    Total calculated
    $223,557
    From this org
    $212,462
    From related orgs
    $0
    Other
    $11,095
    Hours/week
    60

    Schedule J breakdown matched by us

    Base
    $205,882
    Bonus
    $6,580
    Other
    $0
    Deferred
    $8,499
    Nontaxable benefits
    $2,596
    Filer's total
    $223,557

  • Karyn Digiorgio

    CHIEF COLLABORATION OFFICER

    Total calculated
    $311,762
    From this org
    $278,506
    From related orgs
    $0
    Other
    $33,256
    Hours/week
    60

    Schedule J breakdown matched by us

    Base
    $269,680
    Bonus
    $8,826
    Other
    $0
    Deferred
    $6,855
    Nontaxable benefits
    $26,401
    Filer's total
    $311,762

  • Tracey Heather

    DIRECTOR OF DEVELOPMENT

    Total calculated
    $275,344
    From this org
    $231,040
    From related orgs
    $0
    Other
    $44,304
    Hours/week
    60

    Schedule J breakdown matched by us

    Base
    $223,553
    Bonus
    $7,487
    Other
    $0
    Deferred
    $8,314
    Nontaxable benefits
    $35,990
    Filer's total
    $275,344

  • Paul Henderson

    SR. DIRECTOR OF COLLABORATIONS

    Total calculated
    $276,498
    From this org
    $231,615
    From related orgs
    $0
    Other
    $44,883
    Hours/week
    60

    Schedule J breakdown matched by us

    Base
    $224,112
    Bonus
    $7,503
    Other
    $0
    Deferred
    $8,891
    Nontaxable benefits
    $35,992
    Filer's total
    $276,498

  • Maria Pitsiouni

    DIRECTOR, CLINICAL OPERATIONS ONCOLOGY

    Total calculated
    $251,359
    From this org
    $216,516
    From related orgs
    $0
    Other
    $34,843
    Hours/week
    60

    Schedule J breakdown matched by us

    Base
    $211,380
    Bonus
    $5,136
    Other
    $0
    Deferred
    $8,661
    Nontaxable benefits
    $26,182
    Filer's total
    $251,359

  • Sara Horton

    EXECUTIVE DIRECTOR, ACCESS & DIVERSITY

    Total calculated
    $239,763
    From this org
    $235,513
    From related orgs
    $0
    Other
    $4,250
    Hours/week
    60

    Schedule J breakdown matched by us

    Base
    $235,513
    Bonus
    $0
    Other
    $0
    Deferred
    $2,750
    Nontaxable benefits
    $1,500
    Filer's total
    $239,763

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Compensation committee
  • 3 · Form 990 of other organizations
  • 3 · Written employment contract
  • 3 · Compensation survey or study
  • 3 · Approval by the board or compensation committee
  • 7 · Other non-fixed payments

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 8 · Paid under the initial-contract exception

The filer's explanations (Part III)

PART I, LINE 7
DISCRETIONARY BONUSES ARE APPROVED BY THE BOARD OF DIRECTORS.

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

No itemized grants to organizations on this return.

Provenance

Return type
form_990
Tax year
2022
Filed
15 November 2023
IRS schema version
2022v5.0
Source object
202303199349309725

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.